Sign up USA
Proactive Investors - Run By Investors For Investors

Merck shares pop as its Keytruda drug results power ahead of Bristol-Myers, Roche

The immunotherapies boost patient survival rates, studies show
Cancer cell culture seen under a microscope
Unlike chemotherapy and radiation, immunotherapies may have milder side effects

Merck & Co (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY) and Roche Holding AG (VTX: ROG) cancer drugs all beat expectations, but Merck beat them a little more handily.

Merck presented promising results on Monday for its cancer drug Keytruda at the American Association for Cancer Research’s annual meeting.

In a trial known as Keynote-189, Keytruda was shown to reduce the risk of death by 51% when combined with chemotherapy, versus chemotherapy on its own.

“Our goal is to extend the lives of patients with lung cancer, and the unambiguous survival findings from Keynore-189 showing the risk of death was reduced by half in the Keytruda arm are important not only for patients but also for the medical community,” said Dr. Roger M. Perlmutter, president of Merck Research Laboratories, in a press statement.

Shares of Merck rose over 3% in Monday morning trading.

At the same time, Bristol-Myer’s drug, Opdivo, along with another of its medicines, Yervoy, reduced the risk of cancer progression or death in its study by 42% when compared with chemotherapy on its own.

Shares of Bristol-Myers Squibb fell 8% to US$54 after its drug was surpassed by Keytruda’s performance.

Read: Bristol-Myers falls after Citi analyst says Pfizer not interested in buying the drugmaker

New cancer treatments from Merck, Bristol-Myers and Roche that harness the body's immune system are ready to go mainstream, but they come with high price tags because they combine already expensive drugs.

Keytruda and Opdivo each cost about $13,500 monthly per patient.

Roche also shared its progression-free survival data at the conference. According to the study, of the 692 patients that took part in the trial, those that received a combination of the Swiss drug maker’s cancer immunotherapy Tecentriq with one of its other cancer drugs, Avastin, along with carboplatin and paclitaxe had a median progression-free survival of 8.3 months, while the group in the trial that received Avastin and the chemotherapy without the immunotherapy had a median of about 6.8 months.

The World Health Organization estimated that 1.69 million people died of lung cancer in 2015.

Like chemotherapy and radiation, immunotherapies can have side effects, but they tend to look very different than those from immunotherapies.

View full MRK profile View Profile

Merck & Co Timeline

Related Articles

scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use